 |
|
Comparison of New Topical Treatments for Herpes Labialis
Efficacy of Penciclovir Cream, Acyclovir Cream, and n-Docosanol Cream Against Experimental Cutaneous Herpes Simplex Virus Type 1 Infection
Mark B. McKeough, BA;
Spotswood L. Spruance, MD
Arch Dermatol. 2001;137:1153-1158.
Background There are 3 new topical treatments for herpes labialis that have either been approved by the US Food and Drug Administration (penciclovir cream [Denavir] and n-docosanol cream [Abreva]) or recently undergone extensive clinical evaluation (acyclovir cream). The relative efficacy of these products is unknown.
Objective To compare the efficacy of penciclovir cream, acyclovir cream, n-docosanol cream, and acyclovir ointment in an experimental animal model of cutaneous herpes simplex virus type 1 (HSV-1) disease.
Design The backs of guinea pigs were infected with HSV-1 using a vaccination instrument. Active treatments and corresponding vehicle controls were applied for 3 to 5 days beginning 24 hours after inoculation.
Main Outcome Measures After completion of treatment, the animals were killed and the severity of the infection assessed from the number of lesions, the total lesion area, and the lesion virus titer.
Results Penciclovir cream effected modest reductions in lesion number (19%), area (38%), and virus titer (88%) compared with its vehicle control, and each of these differences was significantly greater (P<.05) than the reductions effected by acyclovir ointment (0%, 21%, and 75%, respectively). The acyclovir cream effect (reductions of 4%, 28%, and 77%, respectively) was less than that of penciclovir cream, and this difference was confirmed by 2 additional head-to-head experiments. Two experiments with n-docosanol cream failed to show statistically significant differences by any parameter between n-docasonol cream and vehicle control–treated sites or between n-docosanol and untreated infection sites.
Conclusions In this model, the efficacy of penciclovir cream was greater than acyclovir cream, acyclovir cream was greater than or equal to acyclovir ointment, and acyclovir ointment was greater than n-docosanol cream. Since our model was designed to evaluate compounds that function primarily through antiviral activity, the negative findings with n-docosanol in these studies do not exclude that it might work clinically through other mechanisms.
From the Departments of Medicine (Mr McKeough and Dr Spruance) and Dermatology (Dr Spruance), School of Medicine, and the Department of Pharmaceutics and Pharmaceutical Chemistry (Dr Spruance), College of Pharmacy, University of Utah, Salt Lake City.
RELATED ARTICLES
A Review of Antiviral Therapy for Herpes Labialis
Melody Vander Straten, Daniel Carrasco, Patricia Lee, and Stephen K. Tyring
Arch Dermatol. 2001;137(9):1232-1235.
EXTRACT
| FULL TEXT
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2001;137(9):1262.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
High-Dose, Short-Duration, Early Valacyclovir Therapy for Episodic Treatment of Cold Sores: Results of Two Randomized, Placebo-Controlled, Multicenter Studies
Spruance et al.
Antimicrob. Agents Chemother. 2003;47:1072-1080.
ABSTRACT
| FULL TEXT
A Review of Antiviral Therapy for Herpes Labialis
Vander Straten et al.
Arch Dermatol 2001;137:1232-1235.
FULL TEXT
|
